Porter G M, Armstrong L, Nielsen L L
Department of Laboratory Animal Medicine & Surgery, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Lab Anim Sci. 1995 Apr;45(2):145-50.
In this study we evaluated the antitumor efficacy of taxol in four solid tumor models derived from wap-ras line 69 transgenic mice. Taxol inhibited the growth of spontaneous salivary and mammary gland adenocarcinomas in wap-ras mice. In nude mice it was also effective against solid tumors caused by WR21 cells derived from a wap-ras salivary gland tumor. Taxol was not able to prevent tumor emergence in wap-ras/F mice, a subline of the wap-ras strain in which all males develop palpable mammary gland tumors between 1.5 and 3.0 months of age. Our data indicate the range of results that can be expected when this panel of related transgenic tumor models is used to study the antitumor effects of taxol and other therapeutic drugs that act by affecting tubulin polymerization. These models of ras-mediated neoplasia should prove useful for testing anticancer compounds with taxol-like mechanisms of action.
在本研究中,我们评估了紫杉醇对源自WAP-ras 69系转基因小鼠的四种实体瘤模型的抗肿瘤疗效。紫杉醇抑制了WAP-ras小鼠自发性唾液腺和乳腺腺癌的生长。在裸鼠中,它对由源自WAP-ras唾液腺肿瘤的WR21细胞引起的实体瘤也有效。紫杉醇无法预防WAP-ras/F小鼠(WAP-ras品系的一个亚系,其中所有雄性在1.5至3.0月龄之间会出现可触及的乳腺肿瘤)中肿瘤的出现。我们的数据表明,当使用这组相关的转基因肿瘤模型来研究紫杉醇和其他通过影响微管蛋白聚合起作用的治疗药物的抗肿瘤作用时,可以预期的结果范围。这些ras介导的肿瘤形成模型应该被证明对测试具有紫杉醇样作用机制的抗癌化合物有用。